Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.43 |
| ▸ | CCND1 | P24385 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393616 | 0.81 | CDK4 (0.49) | CDK4CCND1HTR2AHTR2CMAPK1 | |
| SCHEMBL29384135 | 0.80 | CDK4 (0.56) | CDK4CCND1HTR2AHTR2CCYP2A6 | |
| SCHEMBL29812 | 0.80 | CDK4 (0.56) | CDK4CCND1HTR2AHTR2CCYP2A6 | |
| Formaldehyde SCHEMBL27911684 | 0.78 | CDK4 (0.50) | CDK4CCND1HTR2AHTR2CCYP2A6 | |
| Dimethylamine SCHEMBL3332471 | 0.78 | CDK4 (0.50) | CDK4CCND1HTR2AHTR2CCYP2A6 | |
| Bromide SCHEMBL31591097 | 0.78 | CDK4 (0.54) | CDK4CCND1HTR2AHTR2CCYP2A6 | |
| Bromide SCHEMBL6480413 | 0.78 | CDK4 (0.54) | CDK4CCND1HTR2AHTR2CCYP2A6 | |
| Hydrochloric Acid SCHEMBL1356443 | 0.78 | CDK4 (0.54) | CDK4CCND1HTR2AHTR2CCYP2A6 | |
| Hydrochloric Acid SCHEMBL30610362 | 0.78 | CDK4 (0.54) | CDK4CCND1HTR2AHTR2CCYP2A6 | |
| Formic Acid SCHEMBL28280220 | 0.77 | CYP2A6 (0.50) | CDK4CCND1HTR2AHTR2CCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121601-B1 | NOVEL INDOLE DERIVATIVES, METHODS FOR PREPARING SAME, AND USE THEREOF PARTICULARLY AS ANTIBACTERIAL AGENTS | Université Joseph Fourier (FR) | 2016-06-15 | — | — | EP | disclosed |
| US-8343964-B2 | Indolic derivatives, their preparation processes and their uses in particular as antibacterials | UNIVERSITE JOSEPH FOURIER (FR) | 2013-01-01 | — | — | US | disclosed |
| US-20100144726-A1 | NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS | UNIVERSITE JOSEPH FOURIER (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-1134213-B1 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6846820-B2 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. (US) | 2005-01-25 | — | — | US | disclosed |
| EP-1032424-B9 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PROD INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-6649634-B2 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | HOOVER DENNIS J (US) | 2002-03-07 | — | — | US | disclosed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | disclosed |
| EP-1032424-A1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | Pfizer Products Inc. (US) | 2000-09-06 | — | — | EP | disclosed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5952322-A | AMIDE-SUBSTITUTED BENZIMIDAZOLE, INDOLE DERIVATIVES | PFIZER INC. (US) | 1999-09-14 | — | — | US | disclosed |
| WO-1999026659-A1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0846464-A2 | Use of glycogen phosphorylase inhibitor for reducing non-cardiac tissue damage resulting from ischemia | PFIZER INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | CDK4 1468/4885CCND1 2163/4885HTR2A 512/4885 |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | CDK4 1320/4885CCND1 2150/4885HTR2A 477/4885 |
| US-20100144726-A1 | NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS | GPBAR1, TPH1, GPER1 | CDK4 2529/4885CCND1 1259/4885HTR2A 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.